Targeted Therapy for Inflammatory Diseases and Cancer

Description

This technology is a biologic therapy that modulates macrophage activity to redirect immune responses, reduces inflammation, and suppresses tumor growth. Preclinical studies in mouse models show that treatment with this technology significantly reduces tumor burden, decreases metastasis spread, and reshapes the tumor microenvironment. These findings support its potential as a promising therapeutic strategy for both cancer and inflammatory diseases.

Cancer remains one of the most urgent global health challenges, with 20 million new cases and 9.7 million deaths reported worldwide in 2022. According to the Global Cancer Observatory, these numbers are projected to rise to 33 million cases and 18.2 million deaths by 2050. Approximately 1 in 5 people will develop cancer in their lifetime.

Chronic inflammatory diseases are the most significant cause of death in the world. Worldwide, 3 of 5 people die due to chronic inflammatory diseases like stroke, chronic respiratory diseases, heart disorders, cancer, obesity, and diabetes. Despite ongoing advancements in treatment, there remains a critical need for more effective and targeted therapeutic approaches for both cancer and chronic inflammatory diseases.

Benefits

• Reprograms Tumor Microenvironment: Treatment shifted macrophage polarity toward anti-inflammatory, anti-tumor phenotype, and lowered cytokine expression in both breast cancer and melanoma mouse models.
• Reduces Tumor Growth: Treatment led to smaller tumors in both breast cancer and melanoma mouse models.
• Limits Metastasis and Immune Suppression: Treatment decreased metastatic spread, reduced levels of immunosuppressive Tregs, and IL-10 expression in mouse models.
• Inhibits Inflammation: Treatment inhibits fibrosis progression in mouse models of liver, lung, and pancreatic fibrosis.

Applications

• Cancer Immunotherapy
• Anti-Inflammatory Therapeutics

Patent Status

• https://patents.google.com/patent/WO2024044788A2/en?oq=WO2024044788A2

Publications

Extracellular PKM2 modulates cancer immunity by regulating macrophage polarity | Cancer Immunology, Immunotherapy; Pyruvate kinase M2 regulates fibrosis development and progression by controlling glycine auxotrophy in myofibroblasts - PMC